-The Hindu   How a country like India can deny payment of minimum wages, she asks For the second time since it was created, rights activist Aruna Roy has resigned from the Sonia Gandhi-led National Advisory Council (NAC), this time criticising the government for not accepting the council's recommendations on minimum wages to workers under the Mahatma Gandhi National Rural Employment Guarantee Scheme (MGNREGS), even as she thanked the council's chairperson for the...

-The Telegraph The Union health ministry has signalled its intentions to go ahead with plans to introduce a cadre of rural health care providers through a new BSc course, ignoring objections from a parliamentary panel. The ministry told Delhi High Court this week that it had sent a draft cabinet note on the three-and-a-half-year course in community health to the Prime Minister's Office for comments. This is standard procedure before the matter...

-Live Mint The varying demographic trends in modern India could create disagreements in the political system There were 180 million more Indians in 2011 than a decade ago. Around half this increase in population came from the villages and half from the cities. The urban population actually grew slightly more than the rural population, perhaps for the first time in Indian history. The big picture is generally known. It is in the...

-The Times of India NEW DELHI: If the dictum 'you can't manage what you can't measure' is true, then the government has an unsure grip over at least half the 13 flagship schemes worth nearly Rs 2 lakh crore annually, almost 80% of the total spend on central schemes. The government is unable to efficiently collate information to assess whether some of the 13 key flagship schemes are producing the results for...

-The Business Standard USFDA's zero tolerance policy requires our drug firms to reorient not just processes but organisational cultures to serve that market credibly The following two quotes from the United States Food and Drug Administration (FDA) news releases may help put the Ranbaxy controversy in perspective. The first sums up what it is that drives the FDA and the second is typical of the challenge the pharmaceutical industry faces. (1) "The consent...